US 12,404,344 · Application 17/893,515 · Granted Sep 2, 2025
US 12,404,344
Low-viscosity, high concentration evolocumab formulations and methods of making the same
Estimated expiration
April 1, 2039
12y 184d remaining
Earliest effective filing
Feb 22, 2018
+ 20 years
Feb 22, 2038
PTA +403d
Apr 1, 2039
No TD
—
Final
Apr 1, 2039
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- August 23, 2022
- Earliest effective filing
- February 22, 2018
- Issue date
- September 2, 2025
- PTA
- +403 days
- Base expiry (before PTA)
- February 22, 2038
February 22, 2018 + 20 years = February 22, 2038 + 403 PTA days = April 1, 2039
- Divisional of application 15/902,775, filed Feb 22, 2018, issued as US 11,464,857
- PRO62/462,266 — Provisional — not used for base term
- PRO62/462,266 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/893,515 · US 12,404,344
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,404,344: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12404344Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.